Top Markets
#1 EXOD EXOD +56.80%
#2 CoW Protocol CoW Protocol +55.52%
#3 Glidr Glidr +38.71%
#4 Cysic Cysic +28.33%
#5 Walrus Walrus +25.77%
#6 Humanity Humanity +25.08%
#7 Enso Enso +18.12%
#8 Velvet Velvet +16.00%
#9 Tutorial Tutorial +15.35%
#10 OVERTAKE OVERTAKE +15.31%
Coin of the day
EXOD EXOD
Settings
Language
ENGLISH
Currency
USD
Theme
Quantum Genomics S.A. Quantum Genomics S.A.

Quantum Genomics S.A.

ALQGC
Rank in Stocks #37063
Quantum Genomics S.A., a biopharmaceutical firm established in Paris, France,... Quantum Genomics S.A., a biopharmaceutical firm established in Paris, France, in 2005, focuses on creating treatments for cardiovascular ailments. Its therapeutic approach utilizes the brain aminopeptidase A inhibition (BAPAI) platform, primarily addressing high blood pressure (hypertension) and heart failure. The company's key asset, firibastat, is currently undergoing a crucial Phase III study as a standalone therapy for hypertension and is also in clinical trials for heart failure. Additionally, Quantum Genomics is progressing QGC011 for hypertension in combination therapy, and further developing QGC006 and QGC606 to target both hypertension and heart failure.
Share Price
$0.07600875
Last synced: 2024-11-20
Market Cap
$2.06M
Change (1 day)
-0.51%
Change (1 year)
0.00%
Country
FR
Trade Quantum Genomics S.A. (ALQGC)

Category

Healthcare
Revenue for Quantum Genomics S.A. (ALQGC)
Revenue in Dec 2024 TTM: $2.14K
According to Quantum Genomics S.A. latest financial reports the company's current revenue (TTM) is $2.14K. In 2023 the company made a revenue of $21.88K a decrease compared to the revenue in the year 2022 that was $2.70M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Quantum Genomics S.A. from 2009 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $2.14K 20,481.43%
2024 $10.41 -99.95%
2023 $21.88K -99.19%
2022 $2.70M -24.40%
2021 $3.57M 60.20%
2020 $2.23M 28.33%
2019 $1.74M 40,877.53%
2018 $4.24K 0.00%
2017 0.00 0.00%
2016 0.00 -100.00%
2015 $156.51K -60.11%
2014 $392.39K 1,539.89%
2013 $23.93K -5.52%
2012 $25.33K 1.90%
2011 $24.85K -3.18%
2010 $25.67K -6.76%
2009 $27.53K 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 589,224,844.91%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 281,036,684.84%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B 471,909,450.14%
BE